22
Oct
Glenmark Pharmaceuticals Limited (Glenmark Pharma), a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widely-used Teneliglipt in with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita®DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapaglifloz in, (10mg), and Metformin SR(500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes. Glenmark's Zita® medicines have been benefiting 1.75 million Type 2 diabetic patients in India annually. The launch of Zita® DM, the most…
